Bio Platforms

EXCLUSIVE ONLINE CONTENT

4/3/2019

Fusion Pharmaceuticals Announces $105-Million Financing

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.

3/29/2019

Autolus Therapeutics Unveils Next-Generation Technology & Pipeline

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, recently presented insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development.